<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232917</url>
  </required_header>
  <id_info>
    <org_study_id>LLB-2017-01</org_study_id>
    <nct_id>NCT04232917</nct_id>
  </id_info>
  <brief_title>Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.</brief_title>
  <acronym>PAPION</acronym>
  <official_title>Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labo'Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labo'Life</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV) is a prevalent pathogen, the epidemiology of which has mostly been&#xD;
      studied in the uterine cervix and the vagina.&#xD;
&#xD;
      The KCE Report 238Cs (2015) recommends &quot; HR-HPV-positive women should not be offered&#xD;
      colposcopy immediately. Triage should be done using cytology for this purpose. If cytological&#xD;
      abnormalities (ASCUS+) are found, immediate referral should follow for diagnosis and, where&#xD;
      appropriate, treatment. If no abnormalities are observed in triage, the subject should be&#xD;
      offered follow-up testing (cytology) at six months. &quot;.&#xD;
&#xD;
      There is no treatment that is recommended during this lap time. The 2LPAPI® has been&#xD;
      available for more than 20 years, and has received a marketing authorization in Belgium by&#xD;
      the FAMHP. It is used as an immune regulator in the treatment of HR-HPV infections. Since&#xD;
      2LPAPI® has been made available, clinical observational data collected on treated patients&#xD;
      have shown the beneficial effect on the clearance of HPV.&#xD;
&#xD;
      The purpose of this placebo-controlled trial is to evaluate the efficacy of 2LPAPI® on the&#xD;
      clearance of genital HR-HPV infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration will be 24 months with 12 months of inclusion and 12 months of follow-up.&#xD;
      Patients aged between 25 and 45 years who present cervical abnormalities during the routine&#xD;
      screening visit for cervical cancer prevention.&#xD;
&#xD;
      The total number of patients to include will be 284 with 142 patients per group.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      Comparison of the efficacy of 2LPAPI® versus placebo on the clearance of genital HR-HPV&#xD;
      infections after 12 months of follow-up.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Comparison of 2LPAPI® versus placebo on:&#xD;
&#xD;
        -  HR-HPV infection clearance rate at 6-month visits,&#xD;
&#xD;
        -  HR-HPV infection clearance rate by HPV type at 6-month and 12-month visits,&#xD;
&#xD;
        -  Normal cytology,&#xD;
&#xD;
        -  Safety.&#xD;
&#xD;
      Treatment phase:&#xD;
&#xD;
      Group n°1 = 2LPAPI® (6 months of treatment) Group n°2 = Placebo (6 months of treatment)&#xD;
      Post-treatment follow-up phase: 6 months. Treatment will be considered successful if the&#xD;
      clearance of HR-HPV is done and the cytology is normal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the efficacy of 2LPAPI® versus placebo on the clearance of genital HR-HPV infections after 12 months of follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective of the study will be to compare the number of patients with positive HR-HPV infection status observed at 12 months and the number of patients with positive HR-HPV infection status observed at the inclusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of 2LPAPI® versus placebo on HR-HPV infection clearance rate at 6-month visits.</measure>
    <time_frame>6 months</time_frame>
    <description>The objective of this outcome will be to compare the number of patients with positive HR-HPV infection status observed at 6 months and the number of patients with positive HR-HPV infection status observed at the inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of 2LPAPI® versus placebo on HR-HPV infection clearance rate by HPV type at 6-month and 12-month visits.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The objective of this outcome will be to compare the number of patients with specific type of HPV infection observed at 6 and 12 months and the number of patients with specific HPV infection status observed at the inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal cytology</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The objective of this outcome will be to compare the number of patients with normal cytology at 6-month and 12-month visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>2LPAPI® arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2LPAPI®</intervention_name>
    <description>Treatment</description>
    <arm_group_label>2LPAPI® arm</arm_group_label>
    <other_name>2LPAPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 25-45 years,&#xD;
&#xD;
          -  Women of childbearing age under effective contraception,&#xD;
&#xD;
          -  Patient with last cytology less than 3 years and normal or not more than CIN I, and&#xD;
             current cytology presenting ASC-US, AGUS, LSIL, ASC-H, AGC or LSIL+ASC-H or current&#xD;
             diagnosis of CIN I at the cervical smear,&#xD;
&#xD;
          -  Patient with HR-HPV diagnosis at the current cervical collection,&#xD;
&#xD;
          -  Patient reporting a current stable sexual relationship (steady sexual partner during&#xD;
             study duration),&#xD;
&#xD;
          -  Patient having faculties to understand and respect the constraints of the study,&#xD;
&#xD;
          -  Signature of the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnant or breastfeeding woman,&#xD;
&#xD;
          -  Patient presenting HSIL diagnosis at the cytology or CIN II or CIN III diagnosis at&#xD;
             the cervical smear,&#xD;
&#xD;
          -  Patient previously subject to total hysterectomy,&#xD;
&#xD;
          -  Patient under immunotherapy (including immunosuppressive treatment) or&#xD;
             micro-immunotherapy received during last previous 6 months,&#xD;
&#xD;
          -  Patient with known lactose intolerance,&#xD;
&#xD;
          -  Patient who participated in a clinical study in the previous 3-months' period,&#xD;
&#xD;
          -  Patient who is not sufficiently motivated to engage in a follow-up period of 12&#xD;
             months, or likely to travel or to move before the end of the study,&#xD;
&#xD;
          -  Patient with severe immunodeficiency disease requiring long term treatment (*) or&#xD;
             under chemotherapy or radiotherapy,&#xD;
&#xD;
          -  Patient under listed homeopathic or phytotherapy treatment (see protocol),&#xD;
&#xD;
          -  Patient using or addicted to recreational drugs. (*) important renal or respiratory&#xD;
             insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanène BADRI</last_name>
    <phone>491390738</phone>
    <phone_ext>+32</phone_ext>
    <email>hanene.badri@labolife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Médical Le Tilleul</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathanaël DUBOIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique St Jean</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathanaël DUBOIS</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Paul VAN GOSSUM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justine JEHOTTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreea RADULESCU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CHARLIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgium</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah MITRI</last_name>
    </contact>
    <investigator>
      <last_name>Sarah MITRI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgium</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amelie BOUTE</last_name>
    </contact>
    <investigator>
      <last_name>Amelie BOUTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BOLLUE</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel BOLLUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit MOONS</last_name>
    </contact>
    <investigator>
      <last_name>Benoit MOONS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne GODART</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Goffin</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Goffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elodie GADISSEUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas ROYER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet privé</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie VARZOS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Namur - site Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillipe GOFFIN</last_name>
    </contact>
    <investigator>
      <last_name>Anne GODART</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie GADISSEUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel BOLLUE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit MOONS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah MITRI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie VARZOS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas ROYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy GATHY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy GATHY</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

